riskassess
model
demonstr
abil
new
cell
culturebas
vaccin
manufactur
process
reduc
level
adventiti
agent
millionfold
infecti
level
cell
culturederiv
subunit
influenza
vaccin
optaflu
novarti
vaccin
diagnost
produc
use
madindarbi
canin
kidney
mdck
cell
propag
season
viral
strain
altern
embryon
chickenegg
limit
rang
mammalian
virus
grow
mdck
cell
similar
embryon
egg
mdck
cell
act
effect
filter
wide
rang
adventiti
agent
might
introduc
vaccin
product
howev
introduct
altern
cell
substrat
exampl
mdck
cell
vaccin
manufactur
process
requir
thorough
investig
assess
potenti
adventiti
agent
risk
final
product
unlik
event
contamin
occur
risk
assess
take
account
entir
manufactur
process
initi
influenza
viru
isol
blend
trival
subunit
vaccin
worstcas
residu
titr
final
vaccin
formul
calcul
virus
viru
famili
maximum
residu
titr
virus
test
rang
infecti
unit
per
vaccin
dose
thu
new
cell
culturebas
vaccin
manufactur
process
reduc
adventiti
agent
level
unabl
caus
infect
current
avail
inactiv
trival
influenza
vaccin
produc
influenza
viru
propag
egg
relev
influenza
viru
strain
isol
individu
embryon
chickenegg
accord
world
health
organ
annual
recommend
current
vaccin
contain
strain
b
influenza
refer
strain
isol
reassort
circul
strain
highyield
eggadapt
strain
distribut
influenza
vaccin
manufactur
use
strain
produc
viral
seed
lot
use
seed
lot
individu
strain
grown
separ
inocul
embryon
egg
isol
refer
strain
sever
day
incub
viru
harvest
purifi
inactiv
combin
two
purifi
inactiv
influenza
viru
strain
produc
trival
influenza
vaccin
although
eggderiv
vaccin
efficaci
reduc
case
laboratoryconfirm
influenza
ill
healthi
adult
product
vaccin
inflex
limit
avail
egg
furthermor
demand
influenza
vaccin
increas
part
expans
vaccin
recommend
potenti
threat
influenza
pandem
mammalian
cell
cultur
success
employ
propag
influenza
virus
subsequ
influenza
vaccin
manufactur
utilis
mammalian
cell
instead
embryon
egg
viru
propag
potenti
overcom
technic
limit
current
manufactur
practic
includ
long
lead
time
possibl
antigen
mismatch
circul
influenza
strain
trival
subunit
influenza
vaccin
produc
use
madindarbi
canin
kidney
mdck
cell
viru
propag
optaflu
novarti
vaccin
diagnost
nvd
licens
european
medicin
agenc
continu
cell
line
accept
use
vaccin
product
safeti
assess
must
carri
cell
line
vaccin
manufactur
process
confirm
absenc
oncogen
element
exampl
oncogen
viru
viral
gene
cellular
oncogen
well
confirm
viral
safeti
vaccin
assess
includ
test
tumourigen
oncogen
event
induc
intact
cell
cell
lysat
extract
dna
specif
vivo
model
test
oncogen
virus
cell
bank
confirm
remov
intact
cell
vaccin
process
use
specif
measur
remov
degrad
residu
dna
histor
concern
viral
safeti
vaccin
arisen
potenti
incident
introduct
adventiti
agent
vaccin
manufactur
process
case
influenza
vaccin
adventiti
virus
may
present
origin
clinic
isol
may
introduc
passag
refer
strain
embryon
egg
potenti
sourc
contamin
includ
raw
materi
laboratoryprocess
personnel
extern
sourc
biolog
process
carri
adventiti
agent
risk
although
incident
introduct
adventiti
agent
could
occur
convent
eggbas
product
inactiv
influenza
vaccin
vaccin
wellestablish
safeti
profil
limit
suscept
rang
virus
egg
act
filter
wide
rang
agent
therebi
lower
adventiti
agent
risk
quantit
riskassess
model
develop
determin
product
processfailur
risk
pose
adventiti
agent
might
occur
optaflu
manufactur
process
processspecif
assess
consid
element
manufactur
process
utilis
polymeras
chain
reaction
pcr
base
viru
exclus
test
clearanc
capabl
viral
inactiv
potenti
vaccin
manufactur
process
assess
start
earliest
relev
step
isol
influenza
viru
strain
human
throat
sampl
also
consid
egg
passag
isol
influenza
viru
mdck
cell
passag
prepar
viral
seed
pcr
detect
limit
test
materi
extend
entir
manufactur
process
includ
ferment
purif
blend
final
trival
vaccin
riskassess
model
appli
rang
potenti
contamin
allow
estim
maximum
human
infecti
dose
per
vaccin
dose
made
worstcas
scenario
appli
everi
step
manufactur
process
order
adequ
cover
variabl
potenti
viru
titr
viru
passag
number
dilut
inactiv
result
might
occur
differ
viru
type
viru
famili
report
applic
riskassess
model
virus
viru
famili
could
theoret
introduc
manufactur
cell
culturederiv
vaccin
includ
human
agent
herp
viru
adenoviru
coronaviru
enteroviru
reoviru
retroviru
rhinoviru
parainfluenza
viru
pneumoviru
addit
avian
retroviru
reoviru
birnaviru
porcin
circoviru
estim
maximum
residu
titr
per
millilitr
cell
culturederiv
vaccin
calcul
virusesviru
famili
translat
maximum
human
infecti
unit
per
vaccin
dose
mdck
epitheli
cell
line
origin
kidney
healthi
dog
adapt
nvd
grow
freeli
suspend
serumfre
chemic
defin
medium
cell
term
mdck
use
produc
master
cell
bank
work
cell
bank
cell
bank
extens
screen
presenc
adventiti
agent
use
openend
detect
method
includ
convent
vivo
vitro
adventiti
agent
test
specif
test
human
canin
porcin
bovin
rodent
equin
virus
evid
adventiti
agent
either
cell
bank
observ
parent
cell
mdck
cell
bank
also
screen
extens
adventiti
viral
agent
neg
result
refer
influenza
viru
strain
contain
strain
recommend
annual
suppli
collabor
centr
refer
strain
isol
inocul
embryon
chickenegg
human
clinic
sampl
exampl
throat
swab
influenzainfect
individu
influenza
viru
growth
monitor
viru
isol
recov
analys
accord
antigen
genet
phenotyp
select
match
current
circul
influenza
strain
mani
strain
grow
well
embryon
egg
influenza
strain
undergo
reassort
highyield
strain
grow
well
egg
although
risk
coisol
adventiti
agent
alongsid
influenza
viru
reduc
use
high
dilut
inoculum
regular
haemagglutin
test
specif
measur
place
purpos
exclud
test
adventiti
agent
specif
viru
recommend
vaccin
manufactur
nvd
cell
culturederiv
vaccin
manufactur
process
viral
seed
stock
annual
vaccin
prepar
passag
eggadapt
viru
isol
mdck
cell
viru
prepar
passag
adequ
high
titr
frozen
use
work
seed
viru
stock
base
upon
result
risk
assess
work
seedstock
routin
undergo
pcrbase
test
select
adventiti
agent
mdck
cell
cultur
bioreactor
largescal
work
volum
l
bioreactor
inocul
influenza
seed
viru
process
continu
virus
releas
cultur
medium
mdck
cell
remov
centrifug
viruscontain
supernat
harvest
point
sampl
harvest
monoval
viru
bulk
undergo
steril
test
may
subject
pcr
test
influenza
viru
inactiv
incub
bpl
residu
inactiv
agent
hydrolys
elev
temperatur
monoval
bulk
harvest
process
via
chromatographi
purif
concentr
subsequ
process
step
includ
deterg
treatment
disrupt
viral
envelop
follow
separ
extract
surfac
antigen
subunit
viral
core
subsequ
purif
step
employ
polish
concentr
viru
subunit
three
monoval
vaccin
blend
produc
final
trival
vaccin
formul
use
obtain
reput
sourc
includ
american
type
cultur
collect
special
academ
laboratori
genet
serolog
character
possibl
ident
human
adventiti
agent
confirm
independ
pcr
test
except
mammalian
reoviru
pcr
test
perform
max
von
pettenkof
institut
munich
germani
growth
studi
carri
use
standard
experiment
scheme
mdck
suspens
cell
grown
medium
use
vaccin
product
ml
spinner
flask
cell
suspens
inocul
tissu
cultur
infecti
dose
tcid
test
viru
sampl
inocul
suspens
cultur
medium
plu
cell
taken
directli
infect
frozen
thaw
measur
inoculum
titr
standard
viru
titrat
specif
sensit
cell
line
primari
cell
sampl
taken
way
regular
interv
week
inocul
order
monitor
viru
titr
sampl
volum
chosen
specif
keep
cell
densiti
level
would
inhibit
cell
growth
volum
remov
replac
volum
fresh
medium
viru
titrat
perform
use
replic
titrat
test
cultur
n
log
dilut
step
viru
titr
calcul
use
spearmankarb
formula
repeat
intermedi
precis
viru
titrat
typic
vari
standard
deviat
log
inactiv
remov
studi
carri
prerequisit
specif
risk
calcul
bpl
inactiv
process
studi
virus
list
except
cytomegaloviru
variou
influenza
vaccin
viru
strain
second
parvoviru
canin
parvoviru
also
second
herpesviru
pseudorabi
viru
furthermor
strain
porcin
parvoviru
avian
retroviru
avian
birnaviru
studi
gener
worstcas
scenario
cellfre
otherwis
unpurifi
cell
cultur
harvest
pass
ident
bpl
inactiv
process
use
influenza
vaccin
viru
vaccin
manufactur
process
viru
titr
measur
inactiv
calcul
viru
titr
reduct
achiev
inactiv
process
confid
interv
ci
viru
reduct
rate
rang
log
log
influenza
viru
extra
studi
carri
assess
separ
inactiv
capac
bpl
hydrolysi
step
purpos
volum
infecti
viru
spike
process
materi
initi
inactiv
step
perform
remain
viru
titr
measur
hydrolysi
step
inactiv
remov
studi
carri
subunit
split
purif
process
viru
select
studi
govern
risk
occurr
need
provid
broad
represent
virus
term
relev
taxonom
morpholog
physicochem
characterist
reoviru
hsv
rel
stabl
repres
within
spectrum
nonenvelop
envelop
virus
consid
risk
assess
also
repres
like
contamin
may
replic
mdck
cell
well
embryon
egg
use
influenza
viru
isol
murin
leukaemia
viru
mulv
also
test
sinc
viruscontain
retroviru
model
commonli
use
recommend
studi
furthermor
simian
viru
stabl
polyomaviru
also
studi
note
howev
polyomaviru
polyomaviru
sequenc
retroviru
revers
transcriptas
activ
detect
mdck
cell
virus
spike
process
materi
subject
deterg
split
subsequ
subunit
separ
purif
step
sampl
taken
monitor
residu
viru
titr
viru
reduct
rate
calcul
amount
viru
ad
start
materi
care
chosen
high
possibl
order
determin
capac
process
step
inactivateremov
virus
adequ
whilst
time
chang
composit
product
materi
significantli
reproduc
viru
reduct
shown
two
independ
studi
observ
publish
guidanc
viral
safeti
evalu
biotechnolog
product
deriv
cell
line
human
anim
origin
quantit
risk
assess
base
calcul
potenti
adventiti
agent
exposur
amount
could
theoret
present
point
cell
culturederiv
influenza
vaccin
manufactur
process
initi
isol
influenza
viru
strain
egg
blend
final
trival
vaccin
exposur
amount
potenti
adventiti
agent
estim
term
infecti
unit
per
ml
base
publish
data
data
deriv
studi
tabl
specif
viru
titr
data
use
wherev
possibl
eg
growth
adventiti
agent
mdck
cell
limit
detect
pcrbase
viru
exclus
assay
log
reduct
rate
measur
viru
inactiv
deterg
split
separ
section
worstcas
scenario
assum
risk
previous
document
assumpt
made
step
vaccin
product
process
data
assumpt
base
outlin
maximum
titr
log
infecti
unitsml
assum
viral
agent
might
found
origin
clinic
sampl
experi
greatest
viru
titr
may
harvest
optim
cell
cultur
viru
isol
process
clinic
sampl
dilut
least
suitabl
buffer
transport
medium
l
sampl
inocul
egg
take
account
dilut
step
maximum
log
infecti
unitsml
assum
start
viru
titr
potenti
contamin
origin
clinic
sampl
base
assumpt
minimum
three
egg
passag
perform
influenza
viru
isol
characteris
passag
use
dilut
factor
titr
log
infecti
unitsml
calcul
agent
grow
embryon
egg
growth
egg
exclud
restrict
welladapt
viru
expect
slow
andor
ineffect
titr
log
infecti
unitsml
assum
increas
log
infecti
unitsml
growth
particular
agent
embryon
egg
exclud
avian
virus
viru
type
known
grow
well
embryon
egg
maximum
viru
titr
log
infecti
unitsml
assum
l
volum
would
transfer
next
step
result
titr
log
infecti
unitsml
virus
note
much
higher
dilut
repeat
infect
passag
often
util
practic
would
reduc
exclud
contamin
much
effect
estim
assumpt
outlin
tabl
outlin
data
assumpt
includ
worstcas
scenario
necessari
step
manufactur
process
throat
sampl
worstcas
scenario
dilut
l
inocul
result
maximum
titr
viru
isol
passag
use
l
inoculum
per
ml
egg
allanto
fluid
correspond
assumpt
relat
behaviour
adventiti
virus
mdck
cell
cultur
base
data
deriv
viral
growth
studi
section
supplement
data
extract
scientif
literatur
gener
mdck
viral
seed
minimum
three
passag
assum
one
use
minimum
viru
dilut
mdck
cell
support
growth
virus
would
result
viru
titr
reduct
log
infecti
unitsml
viru
present
cell
cultur
howev
stabl
human
agent
unabl
grow
mdck
cell
may
contamin
seed
viru
passag
open
step
carri
human
oper
necessari
assum
calcul
possibl
intermitt
contamin
oper
assum
contamin
infecti
unitsml
via
aerosol
contamin
equip
total
volum
l
infect
smallest
cultur
volum
use
ml
result
final
viru
content
log
infecti
unitsml
cultur
fluid
worstcas
scenario
viru
titr
could
remain
stabl
without
reduct
degrad
passag
dilut
particularli
contamin
occur
last
cultur
step
residu
viru
titr
log
infecti
unitsml
also
assum
human
virus
agent
specif
data
avail
growth
mdck
cell
would
highli
unlik
virus
grow
mdck
cell
specif
titr
measur
viral
growth
studi
describ
previous
carri
ident
condit
appli
mdck
cultur
passag
influenza
viru
use
section
pcr
limit
detect
measur
term
log
infecti
unitsml
appli
virus
specif
pcr
test
includ
calcul
pcr
test
includ
calcul
calcul
titr
viral
seed
alreadi
reduc
detect
limit
pcr
test
residu
viru
titr
calcul
step
maintain
bioreactor
inocul
step
least
dilut
seed
viru
assum
occur
use
inocul
largescal
bioreactor
cell
cultur
would
result
reduct
adventiti
viru
least
log
infecti
unitsml
practic
higher
dilut
normal
use
maximum
residu
titr
measur
day
ferment
appli
virus
grow
mdck
cell
section
agent
grow
mdck
cell
unlik
grow
mdck
cell
worstcas
scenario
titr
loss
assum
residu
titr
previou
step
carri
forward
pcr
test
bioreactor
harvest
includ
calcul
relev
detect
limit
pcr
test
taken
postferment
titr
chromatographi
step
carri
purifi
concentr
influenza
virus
may
also
concentr
virus
result
higher
viru
titr
concentr
intermedi
product
gener
specif
data
process
step
virusspik
raw
product
process
chromatographi
step
viru
titr
remain
intermedi
product
measur
chromatographi
step
lead
increas
viru
concentr
three
virus
test
hsv
mulv
reoviru
fact
viru
titr
reduct
observ
risk
assess
lowest
averag
sum
reduct
appli
virus
log
infecti
unitsml
reduct
observ
reoviru
calcul
maximum
degre
viru
concentr
could
occur
purif
process
lowest
yield
variou
influenza
viru
strain
observ
develop
vaccin
manufactur
process
use
calcul
amount
viru
harvest
need
produc
ml
monoval
bulk
concentr
lowest
yield
observ
log
concentr
would
requir
arriv
potent
monoval
concentr
therefor
virus
assess
concentr
factor
log
includ
calcul
account
maximum
possibl
concentr
viru
could
occur
factor
repres
total
effect
sever
downstream
dilut
concentr
step
calcul
maximum
residu
adventiti
viru
titr
bpl
inactiv
step
base
data
deriv
inactiv
studi
relev
virus
section
necessari
repres
select
viru
strain
subtyp
one
definit
valu
avail
viru
type
taxonom
group
lowest
viru
titr
reduct
use
defin
valu
measur
result
incomplet
inactiv
sever
viru
type
group
show
complet
inactiv
ie
reduct
rate
greater
equal
measur
valu
highest
viru
titr
reduct
measur
employ
case
inactiv
rate
taken
relat
virus
exampl
calcul
mump
viru
measl
viru
deduc
lowest
valu
measur
member
paramyxovirida
human
retrovirus
calcul
data
obtain
avian
retroviru
human
hepat
virus
b
c
g
inactiv
rate
assum
similar
rel
resist
hsv
avian
circoviru
assum
equal
well
inactiv
porcin
circoviru
residu
viru
titr
follow
deterg
split
subunit
purif
stage
base
data
studi
repres
select
virus
section
two
envelop
virus
hsv
mulv
complet
inactiv
deterg
treatment
step
reduct
rate
log
infecti
unitsml
report
deterg
treatment
step
nonenvelop
virus
less
affect
deterg
treatment
affect
subsequ
separ
process
reduct
log
step
report
reoviru
log
step
ci
viru
reduct
rate
rang
log
log
purpos
risk
assess
reduct
log
infecti
unitsml
assum
nonenvelop
virus
except
reoviru
close
relat
birnaviru
reduct
log
appli
reduct
log
infecti
unitsml
assum
herpesvirus
log
reduct
envelop
virus
know
valu
would
grossli
underestim
true
reduct
contamin
envelop
viru
occur
trival
subunit
influenza
vaccin
suppli
ml
dose
maximum
ml
monoval
bulk
use
formul
final
trival
subunit
vaccin
would
correspond
reduct
viral
contamin
log
howev
three
combin
monoval
bulk
contain
amount
adventiti
viru
correspond
volum
reduct
would
log
although
formul
final
product
normal
associ
dilut
adjust
vaccin
correct
antigen
concentrationpot
dilut
taken
consider
purpos
risk
assess
worstcas
assumpt
log
reductionml
made
virus
test
infecti
dose
measur
sensit
vitro
system
normal
surpass
anim
human
infecti
dose
order
magnitud
correl
vitro
titr
human
infecti
dose
best
deduc
live
vaccin
mump
measl
rubella
varicella
zoster
polio
vaccin
must
contain
minimum
vitro
titr
infecti
unit
reliabl
establish
infect
vaccin
individu
purpos
risk
assess
minimum
vitro
infecti
unit
assum
suffici
establish
infect
human
specif
data
agent
test
studi
exist
viru
known
infect
human
exampl
avian
reoviru
calcul
may
inadequ
suffici
evid
case
absolut
exclud
human
infect
decid
calcul
final
viru
titr
method
risk
assess
appropri
countermeasur
concentr
agent
abl
replic
mdck
cell
extens
test
wide
rang
virus
perform
determin
abil
grow
mdck
cell
ascertain
relev
potenti
risk
perspect
inactiv
mdck
cell
culturederiv
influenza
vaccin
tabl
studi
demonstr
abil
mdck
cell
support
growth
limit
number
human
virus
hsv
parainfluenza
mammalian
reoviru
grow
effici
mdck
cell
agreement
publish
data
mdck
cell
hsv
parainfluenza
grew
high
titr
log
infecti
unitsml
wherea
reoviru
grew
slowli
prolifer
welladapt
measl
viru
strain
albeit
slow
growth
also
report
conflict
report
publish
literatur
concern
abil
rsv
grow
mdck
cell
wherea
earlier
studi
report
increas
rsv
titr
inocul
mdck
cell
other
report
mdck
cell
show
high
degre
resist
rsv
evalu
differ
cell
substrat
isol
rsv
clinic
specimen
two
rsv
posit
isol
found
mdck
cell
compar
least
posit
isol
cell
substrat
viru
growth
studi
monitor
growth
cell
cultureadapt
rsva
rsvb
strain
serumfre
condit
mdck
suspens
cell
reveal
evid
viru
growth
viru
titr
persist
drop
detect
limit
within
day
thu
possibl
growth
rsv
mdck
cell
seem
restrict
certain
strain
yield
moder
viru
titr
especi
mdck
cell
cultur
coinfect
influenza
viru
mdck
cell
support
growth
avian
virus
may
allow
replic
avian
reoviru
limit
degre
publish
studi
report
inabl
mdck
cell
support
avian
reoviru
propag
howev
replic
studi
demonstr
minor
avian
reoviru
titr
increas
inocul
mdck
cell
high
titr
avian
reoviru
thu
minor
restrict
growth
assum
although
observ
titr
increas
inocul
test
cultur
could
also
due
dissoci
viral
aggreg
risk
assess
cover
spectrum
adventiti
virus
might
encount
cell
culturederiv
influenza
vaccin
manufactur
process
also
includ
broad
select
viral
agent
repres
major
viral
morpholog
taxonom
physic
properti
includ
dna
rna
virus
envelop
nonenvelop
virus
doublestrand
singlestrand
circular
dnarna
genom
small
larg
complex
viral
genom
virus
low
intermedi
extrem
high
stabil
applic
riskassess
model
influenza
viru
potenti
contamin
parainfluenza
viru
adenoviru
reoviru
bk
polyomaviru
describ
detail
tabl
potenti
contamin
repres
differ
scenario
virus
capabl
grow
mdck
cell
envelop
nonenvelop
virus
stabl
unstabl
virus
gener
process
effect
exampl
process
dilut
concentr
step
appli
virus
way
describ
within
context
residu
influenza
viru
titr
virusspecif
effect
riskmodel
discuss
virus
overal
estim
maximum
titr
per
vaccin
dose
virusesviru
famili
test
present
tabl
influenza
viru
envelop
viru
contain
neg
strand
rna
genom
line
riskassess
model
maximum
log
infecti
unitsml
assum
present
origin
clinic
sampl
take
account
inoculum
volum
titr
may
reduc
passag
step
howev
mdck
cell
highli
permiss
influenza
viru
growth
maximum
residu
titr
log
infecti
unitsml
assum
present
bioreactor
harvest
appli
gener
riskassess
assumpt
chromatographi
process
concentr
step
maximum
residu
titr
log
infecti
unitsml
expect
point
manufactur
process
bpl
incub
bpl
hydrolysi
step
assess
inactiv
potenti
combin
result
step
demonstr
capac
process
inactiv
influenza
viru
log
infecti
unitsml
result
maximum
residu
titr
log
infecti
unitsml
inactiv
process
reduct
log
infecti
unitsml
assum
occur
split
viral
envelop
base
data
deriv
studi
envelop
virus
hsv
mulv
final
blend
trival
vaccin
assum
reduc
maximum
residu
titr
log
infecti
unitsml
describ
riskassess
model
may
translat
log
human
infecti
dose
influenza
per
vaccin
dose
human
adenoviru
nonenvelop
viru
doublestrand
dna
genom
maximum
log
infecti
unitsml
assum
present
origin
clinic
sampl
adenoviru
may
grow
egg
maximum
residu
titr
log
infecti
unitsml
assum
present
eggderiv
inoculum
use
subsequ
mdck
cultur
describ
section
contamin
human
oper
assum
occur
finalstag
passag
mdck
cell
cultur
titr
log
infecti
unit
stabl
virusml
assum
present
mdckderiv
viral
seed
pcr
test
viral
seed
incorpor
adenoviru
calcul
known
detect
limit
log
infecti
unitsml
indic
maximum
residu
titr
could
present
stage
manufactur
process
adenoviru
doublestrand
genom
rel
resist
nucleic
acid
destruct
bpl
demonstr
inactiv
studi
three
human
adenovirus
one
canin
adenoviru
minimum
reduct
log
step
observ
studi
split
subunit
purif
step
reduc
stabl
nonenvelop
doublestrand
dna
viru
log
step
appli
adenoviru
theoret
maximum
residu
titr
log
infecti
unitsml
might
remain
purifi
monoval
bulk
stage
manufactur
process
result
final
maximum
residu
titr
log
infecti
unitsml
final
trival
vaccin
translat
potenti
log
human
infecti
dose
per
vaccin
dose
human
parainfluenza
viru
envelop
viru
neg
strand
rna
genom
parainfluenza
viru
grow
egg
maximum
residu
titr
log
infecti
unitsml
assum
present
eggderiv
inoculum
use
inocul
mdck
cell
viru
growth
studi
parainfluenza
shown
replic
quickli
high
titr
mdck
cell
maximum
residu
titr
log
infecti
unitsml
observ
day
cultur
use
cell
cultureadapt
parainfluenza
strain
valu
taken
maximum
residu
titr
could
theoret
present
mdck
seed
viru
pcr
test
work
viral
seed
routin
carri
theoret
maximum
parainfluenza
titr
could
remain
would
correspond
pcr
detect
limit
parainfluenza
pcr
assay
log
infecti
unitsml
valu
may
increas
process
concentr
maximum
log
significantli
reduc
bpl
inactiv
deterg
treatment
subunit
purif
complet
inactiv
two
parainfluenza
strain
bpl
demonstr
inactiv
studi
reduct
log
infecti
unitsml
measur
base
data
deriv
studi
use
envelop
virus
hsv
mulv
log
reduct
parainfluenza
titr
assum
occur
split
subunit
purif
stage
manufactur
process
highli
like
valu
underestim
real
capac
purif
stage
remov
parainfluenza
viru
inactiv
studi
hsv
mulv
first
deterg
step
success
remov
contamin
viru
subsequ
separ
step
could
assess
term
inactiv
potenti
includ
subsequ
manufactur
step
theoret
maximum
titr
log
infecti
unitsml
could
remain
cell
culturederiv
vaccin
parainfluenza
contamin
event
occur
accord
assumpt
defin
translat
potenti
log
human
infecti
dose
per
vaccin
dose
bk
polyomaviru
extrem
stabl
nonenvelop
viru
doublestrand
dna
genom
viru
widespread
natur
primari
infect
like
remain
latent
immunocompet
subject
potenti
pathogen
immunocompromis
individu
bk
polyomaviru
serv
good
model
assess
viral
safeti
particularli
stabl
viru
extrem
difficult
inactiv
remov
contamin
materi
data
avail
permiss
embryon
egg
bk
polyomaviru
maximum
log
infecti
unitsml
assum
bk
polyomaviru
grow
mdck
cell
experi
intermitt
contamin
assum
occur
finalstag
passag
mdck
cell
cultur
result
titr
log
infecti
unitsml
see
section
pcr
detect
limit
bk
polyomaviru
log
infecti
unitsml
therefor
maximum
amount
bk
polyomaviru
could
theoret
remain
mdck
influenza
seed
viru
log
infecti
unitsml
line
doublestrand
genom
virus
exampl
herp
reoviru
birnaviru
bk
polyomaviru
resist
chemic
inactiv
accordingli
bpl
caus
rel
small
reduct
log
step
assumpt
regard
remov
bk
polyomaviru
subunit
purif
stage
manufactur
process
base
data
deriv
virusspik
studi
carri
viru
titr
reduct
log
observ
appli
bk
polyomaviru
take
account
subsequ
manufactur
step
maximum
residu
titr
log
human
infecti
dose
per
vaccin
dose
could
theoret
remain
vaccin
contamin
event
occur
avian
reoviru
nonenvelop
doublestrand
rna
viru
growth
support
embryon
egg
although
avian
reoviru
would
present
origin
clinic
isol
maximum
titr
log
infecti
unitsml
assum
egg
isol
viru
could
present
embryon
egg
use
influenza
viral
strain
isol
previou
studi
demonstr
growth
avian
reoviru
mdck
cell
studi
shown
titr
increas
avian
reoviru
inocul
high
titr
trypsincontain
mdck
cell
cultur
log
infecti
unitsml
rise
log
infecti
unitsml
although
unclear
whether
titr
increas
due
viru
growth
result
dissoci
viru
aggreg
viral
titr
log
infecti
unit
assum
repeat
seed
viru
passag
mdck
cell
bioreactor
harvest
maximum
titr
increas
observ
high
viru
titr
inoculum
day
cultur
taken
result
end
valu
titr
reduct
due
pcr
test
avian
reoviru
calcul
inactiv
studi
demonstr
log
infecti
unitsml
reduct
avian
reoviru
uconn
prototyp
strain
titr
follow
treatment
bpl
complet
inactiv
also
achiev
anoth
field
isol
avian
reoviru
much
greater
inactiv
seen
bpl
treatment
mammalian
reoviru
viru
reduct
subunit
purif
process
log
infecti
unitsml
measur
reoviru
also
appli
avian
reoviru
maximum
log
infecti
unitsml
could
theoret
present
end
purif
process
translat
worstcas
scenario
log
infecti
unitsml
present
final
trival
vaccin
log
human
infecti
dose
per
final
trival
vaccin
dose
although
avian
reoviru
known
infect
human
appli
risk
assess
variou
virusesviru
famili
maximum
infect
titr
log
log
infecti
unit
per
vaccin
dose
calcul
tabl
lack
growth
embryon
egg
mdck
cell
assum
human
herp
virus
human
hepat
virus
b
c
g
human
retrovirus
base
upon
current
knowledg
restrict
host
spectrum
virus
confirm
neg
result
systemat
literatur
search
pcr
test
includ
calcul
virus
inactiv
rate
base
data
obtain
closest
model
viru
lowest
inactiv
rate
obtain
differ
herpesvirus
also
appli
herpesvirus
hepat
b
c
g
virus
inactiv
rate
measur
avian
retroviru
appli
human
retrovirus
porcin
circoviru
could
potenti
contamin
vaccin
process
stream
trypsin
porcin
origin
use
manufactur
process
small
stabl
virus
may
view
worstcas
contamin
vaccin
manufactur
process
includ
risk
assess
porcin
circoviru
also
use
model
avian
circovirus
avian
circoviru
demonstr
strict
hostcel
tropism
base
inform
avail
limit
growth
embryon
egg
growth
mdck
cell
assum
result
previou
report
contamin
unknown
sourc
largescal
ferment
rodent
cell
mvm
parvoviru
also
includ
studi
model
calcul
risk
assess
also
appli
two
bacteri
pathogen
mycoplasma
chlamydia
mycoplasma
common
cell
cultur
contamin
import
assess
effect
manufactur
process
would
event
contamin
note
growth
studi
reveal
mycoplasma
hyorhini
strain
isol
cell
cultur
contamin
rhinoviru
isol
unabl
grow
chemic
defin
serumfre
mdck
cultur
use
seedlot
passag
ferment
grew
rapidli
high
titr
low
amount
serum
ad
cultur
chlamydia
contamin
detect
common
bacteri
steril
test
deem
necessari
also
assess
calcul
effect
contamin
base
data
deriv
growth
studi
inactiv
studi
specif
manufactur
process
capabl
reduc
agent
log
human
infecti
dose
per
vaccin
dose
influenza
viral
seed
produc
annual
basi
match
drift
influenza
strain
refer
virus
releas
vaccin
manufactur
recommend
publish
vaccin
must
manufactur
test
distribut
within
month
order
meet
vaccin
schedul
short
timelin
convent
broadspectrum
test
viral
seed
adventiti
agent
perform
manufactur
commenc
may
even
complet
distribut
final
trival
vaccin
thu
new
inactiv
influenza
vaccin
manufactur
process
design
remov
potenti
contamin
introduc
via
viral
seed
extens
viral
test
mdck
cell
part
standard
process
cell
substrat
evalu
reveal
contamin
cell
line
furthermor
measur
develop
ensur
safeti
margin
exceed
potenti
level
contamin
measur
includ
viru
inactiv
process
rapid
test
specif
viru
detect
eg
pcr
test
proof
effect
viru
remov
deterg
split
subunit
purif
process
contamin
risk
cell
culturederiv
vaccin
manufactur
process
assess
necessari
determin
virus
actual
grow
cell
substrat
order
determin
relev
agent
context
contamin
risk
data
deriv
publish
literatur
comprehens
resourc
replic
studi
carri
assess
growth
characterist
virusesviru
famili
mdck
cell
data
deriv
replic
studi
confirm
mdck
cell
support
growth
limit
rang
virus
context
relev
virus
influenza
viru
parainfluenza
viru
reoviru
herp
simplex
viru
similar
virus
grow
egg
therefor
like
embryon
egg
use
current
influenza
vaccin
manufactur
mdck
cell
act
effect
viral
filter
wide
rang
adventiti
agent
moreov
mdck
cell
support
replic
mani
avian
virus
particular
relev
avian
viru
contamin
introduc
process
passag
vaccin
viru
strain
egg
therefor
use
mdck
cell
viru
propag
lower
productand
processfailur
risk
convers
viral
agent
abil
grow
well
mdck
cell
name
parainfluenza
viru
hsv
reoviru
consider
need
use
model
describ
assess
abil
cell
culturederiv
influenza
vaccin
manufactur
process
reduc
rang
potenti
contamin
level
far
infecti
dose
maximum
titr
log
residu
infecti
unit
per
dose
mdckbase
vaccin
calcul
relev
potenti
adventiti
agent
figur
indic
risk
factor
exampl
end
result
log
mean
one
one
million
vaccin
dose
contain
enough
viru
infect
human
instead
data
refer
infecti
unit
indic
level
viru
anticip
manufactur
vaccin
word
contamin
event
occur
vaccin
manufactur
process
theoret
million
dose
batch
vaccin
would
administ
one
individu
deliv
infecti
dose
variabl
data
use
calcul
describ
impact
outcom
assess
studi
demonstr
averag
ci
log
infecti
unitsml
independ
viru
inactiv
viru
remov
step
similar
ci
viru
growth
titr
suggest
combin
variabl
unlik
exceed
log
infecti
unitsml
manufactur
step
consid
assess
assum
similar
variabl
stage
manufactur
virolog
differ
also
impact
assess
outcom
commonli
use
model
viru
polyomavirus
studi
bpl
inactiv
rate
exceed
measur
bk
polyomaviru
avian
polyomaviru
log
step
similarli
avian
reovirus
highli
sensit
bpl
inactiv
wherea
mammalian
reoviru
relat
birnaviru
much
resist
differ
inactiv
rate
rang
log
step
inactiv
rate
enterovirida
also
vari
differ
log
step
observ
consist
inactiv
rate
observ
adenoviru
rhinoviru
herpesviru
famili
paramyxovirida
famili
contamin
ever
detect
risk
calcul
present
could
also
use
predict
consequ
action
requir
address
event
best
case
calcul
underli
studi
may
use
convinc
evid
action
need
process
abl
remov
inactiv
contamin
critic
relev
influenza
vaccin
seed
viru
strain
readili
exchang
anoth
strain
timeconsum
measur
remov
adventiti
agent
may
longer
possibl
contamin
detect
late
annual
vaccinemanufactur
period
model
whole
process
may
also
help
identifi
viru
exclus
test
need
exampl
virus
grow
high
titr
adequ
remov
inactiv
moreov
viru
titr
calcul
relev
step
entir
process
also
indic
exclus
test
use
exampl
tabl
seen
exclus
test
adenoviru
would
appropri
model
process
conduct
bioreactor
harvest
stage
downstream
expect
worstcas
viral
titr
would
method
detect
limit
convers
calcul
show
test
reovirus
may
use
identifi
contamin
reoviru
although
comfort
high
safeti
margin
risk
assess
indic
measur
absolut
necessari
calcul
present
valid
capac
cell
culturederiv
influenza
vaccin
manufactur
process
remov
andor
inactiv
type
potenti
contamin
conclud
risk
exposur
adventiti
agent
vaccin
produc
mdck
cell
use
specif
manufactur
process
neglig
current
influenza
vaccin
product
incorpor
exclus
test
avian
retroviru
reli
filter
effect
embryon
egg
riskassess
model
describ
provid
control
safeguard
method
assess
potenti
impact
adventiti
agent
manufactur
trival
subunit
influenza
vaccin
